|1.||Zugmaier, Gerhard: 10 articles (12/2015 - 08/2008)|
|2.||Nagorsen, Dirk: 9 articles (01/2015 - 06/2009)|
|3.||Baeuerle, Patrick A: 9 articles (06/2013 - 08/2008)|
|4.||Kufer, Peter: 7 articles (12/2012 - 08/2008)|
|5.||Viardot, Andreas: 6 articles (12/2015 - 08/2008)|
|6.||Klinger, Matthias: 6 articles (12/2015 - 08/2008)|
|7.||Bargou, Ralf C: 6 articles (12/2015 - 03/2009)|
|8.||Einsele, Hermann: 5 articles (12/2015 - 08/2008)|
|9.||Stelljes, Matthias: 5 articles (12/2015 - 06/2011)|
|10.||Topp, Max S: 5 articles (12/2015 - 06/2011)|
|1.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/01/2015 - "Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia."
07/01/2014 - "Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab."
12/10/2015 - "This long-term follow-up analysis evaluated overall survival (OS) and relapse-free survival (RFS) in a phase 2 study of the bispecific T-cell engager antibody construct blinatumomab in 36 adults with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). "
12/20/2014 - "Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia."
01/01/2016 - "Blinatumomab was approved through an accelerated pathway for the treatment of Philadelphia (Ph) chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). "
10/01/2015 - "In the phase II trial that served as the basis for approval, blinatumomab demonstrated significant single-agent activity and induced remission [complete remission (CR) and CR with incomplete recovery of peripheral blood counts (CRh)] in 43% of 189 adult patients with RR-ALL; the majority of responders (82%) also attained negative minimal residual disease (MRD(-)) status that did not generally translate into long-term remissions in most cases. "
01/01/2015 - "The bispecific T-cell-engaging antibody, blinatumomab, targets CD19 and has demonstrated encouraging results in minimal residual disease positive and relapsed/refractory pre-B ALL. "
10/01/2011 - "Blinatumomab: a novel agent to treat minimal residual disease in patients with acute lymphoblastic leukemia."
11/01/2013 - "The new bispecific antibody blinatumomab combines single chain antibodies to CD19 and CD3, and thereby T cells lyse the CD19 bearing B cells and is effective in patients with positive minimal residual disease (MRD) or refractory/relapsed ALL. "
01/01/2015 - "In the first clinical trial, blinatumomab showed efficacy in non-Hodgkin's lymphomas, but the most important trials have been conducted in relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) and in ALL with minimal residual disease. "
08/15/2008 - "Blinatumomab also led to clearance of tumor cells from bone marrow and liver. "
08/15/2014 - "19-3-19 mediated up to 95 % specific lysis of CD19-positive tumor cells and, at picomolar EC₅₀ doses, had similar cytolytic potency as the clinically successful agent Blinatumomab. "
12/01/2013 - "The potent cytotoxic action of blinatumomab on tumor cells appears to involve conjugation of T cells with tumor cells at both the activation and effector stages. "
12/01/2013 - "However, only blinatumomab was able to induce tumor cell death and this was found to require blinatumomab-mediated conjugate formation between T cells and tumor cells. "
06/01/2009 - "With blinatumomab (MT103) a first antibody, which can potentially engage all cytotoxic T cells of a patient for tumor cell lysis, is now available for clinical evaluation. "
|4.||Bites and Stings (Sting)
09/01/2015 - "Blinatumomab is a novel BiTE therapeutic monoclonal antibody that has shown promising results in patients with relapsed or refractory ALL or those achieving a CR with persistent MRD. "
10/01/2015 - "Blinatumomab, a bispecific antibody construct targeting CD19, is the most advanced member of bispecific T-cell engager (BiTE(®)) molecules. "
09/01/2015 - "Blinatumomab is a first-in-class bispecific T-cell engager (BiTE) antibody derived from a B-lineage specific antitumor mouse monoclonal antibody that binds to both CD19 of B-cells and CD3 of T-cells. "
09/01/2015 - "National Institutes of Health Clinicaltrials.gov, the Food and Drug Administration, and relevant meeting abstracts was conducted using the terms blinatumomab, BiTE, bispecific T-cell engager, MT103, MEDI-538, and Blincyto. "
05/13/2015 - "Encouraging clinical data have been reported with molecules such as the anti-CD19/CD3 bispecific T cell engager (BiTE) blinatumomab. "
05/01/2015 - "Although blinatumomab seems an unlikely option for treating indolent lymphoma due to toxicity, the need for long-term continuous infusion therapy and multiple promising well-tolerated oral agents, it holds promise for aggressive NHL patients whose diseases are refractory to current standard approaches. "
11/01/2014 - "In support of their functional capacity, we observed that BET, in combination with blinatumomab, had significant therapeutic activity in a systemic human diffuse large B lymphoma model in NOD-SCID mice. "
06/01/2013 - "Blinatumomab, a CD19/CD3-bispecific BiTE® antibody, has demonstrated high clinical activity in B cell leukemia and lymphoma patients. "
03/01/2009 - "Blinatumomab consistently led to a higher degree of lysis of human lymphoma lines than rituximab, and was active at much lower concentration. "
03/01/2009 - "Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells."
|3.||type 6,11,16,18 human papillomavirus vaccine L1 (Gardasil)
|4.||Antigen Receptors (Antigen Receptor)
|2.||Hematopoietic Stem Cell Transplantation
|4.||Drug Therapy (Chemotherapy)